anonymous
Guest
anonymous
Guest
I can’t believe what I’m reading. Steglatro was supposed to be a Blockbuster drug. Best in class efficacy didn’t stand a chance with our Marketing team. It’s sad Merck couldn’t design a trial that showed some CV or CHF benefit. I guess Merck didn’t learn anything from ENHANCE!!!